Stable expression of BRAF D594F or KRAS L19F in the CET-sensitive DiFi CRC cell line confirmed that each was individually able to maintain a moderate level of pERK despite CET treatment (Figure 3A), supporting a mechanistic role in resistance. This evidence concerns the gene KRAS and colorectal carcinoma.